Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low- versus high-dose atorvastatin and rosuvastatin for inflammatory marker reduction in diabetic adults
IRCT20180929041169N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of atorvastatin and rosuvastatin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: high-sensitivity C-reactive protein and interleukin-6. Started Sep 2018; status: completed.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20180929041169N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180929041169N2.